Christopher R. Chapple

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a beta(3)-Adrenoceptor Agonist, in Overactive Bladder

2013 | Faculty of Medicine in Pilsen

Publication